TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31377161

Group type: EXPERIMENTAL
Intervention: Moderate hypofractionation (MH-RT; 26 fractions of 2.7 Gy to a total dose of 70.2 Gy)
Number of subjects: 421

Group type: COMPARATOR
Intervention: Extreme hypofractionation (EH-RT; fractions of 6.5-7 Gy to a total dose of 32.5-35 Gy)
Number of subjects: 421
Study: 31377265

Group type: EXPERIMENTAL
Intervention: Triac (350 μg initial dose, escalating in 350 μg increments)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Triac (mean dose of 38.3 μg/kg, range 6.4-84.3 μg/kg)
Number of subjects: 46
Study: 31377502

Group type: EXPERIMENTAL
Intervention: Greater relationship satisfaction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Relationship satisfaction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Intermediate variables (depression, communication satisfaction)
Number of subjects: 150
Study: 31377694

Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiotherapy (SBRT) with doses of 5×6, 6×6, or 5×5 Gy
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Salvage stereotactic body radiotherapy (SBRT)
Number of subjects: 47
Study: 31377712

Group type: EXPERIMENTAL
Intervention: Biopsychosocial model of resilience interventions tailored to young patients' specific needs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-report questionnaires assessing psychological distress, coping strategies, QoL, psychological well-being, and resilience
Number of subjects: 0
Study: 31377771

Group type: EXPERIMENTAL
Intervention: Hand-assisted laparoscopy
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Robot-assisted laparoscopy
Number of subjects: 264

Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Standard laparoscopy
Number of subjects: 264
Study: 31377849

Group type: EXPERIMENTAL
Intervention: Canaloplasty combined with phacoemulsification
Number of subjects: 15
Study: 31377946

Group type: EXPERIMENTAL
Intervention: HPV4 + Tdap + MenACWY
Number of subjects: 801

Group type: COMPARATOR
Intervention: HPV4 + Tdap + Placebo
Number of subjects: 801
Study: 31378080

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention (6-week group mindfulness intervention)
Number of subjects: 26
Study: 31378084

Group type: EXPERIMENTAL
Intervention: Androgen-deprivation therapies (ADTs)
Number of subjects: 6560565

Group type: EXPERIMENTAL
Intervention: Enzalutamide and other ADTs
Number of subjects: 6560565
Study: 31378102

Group type: EXPERIMENTAL
Intervention: Integration of tubule biomarkers into prognostic scores
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clinical kidney measures (eGFR and albuminuria)
Number of subjects: 0
Study: 31378427

Group type: EXPERIMENTAL
Intervention: Portable Organ Care System (OCS) Lung perfusion and ventilation
Number of subjects: 93
Study: 31378459

Group type: EXPERIMENTAL
Intervention: Tislelizumab 200 mg every 3 weeks plus pamiparib 40 mg twice daily (recommended phase 2 dose)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Pamiparib with tislelizumab
Number of subjects: 49
Study: 31378656

Group type: EXPERIMENTAL
Intervention: Higher BMI
Number of subjects: 3155

Group type: EXPERIMENTAL
Intervention: Lower BMI
Number of subjects: 3155
Study: 31378693

Group type: EXPERIMENTAL
Intervention: Organizational Infrastructure Paediatric Plan (OIPP)
Number of subjects: 1636
Study: 31378695

Group type: EXPERIMENTAL
Intervention: 8-gene assay (CXCL10, FCGR1A, FCGR1B, GBP1, GBP4, IL15, KLRC1, TIMP1)
Number of subjects: 387

Group type: EXPERIMENTAL
Intervention: 8-gene assay
Number of subjects: 387
Study: 31379605

Group type: EXPERIMENTAL
Intervention: Aquatic endurance training (2-week, twice daily)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Land-based exercise training (2-week, twice daily)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 89
Study: 31379673

Group type: EXPERIMENTAL
Intervention: Compassion-Focused Therapy (CFT)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Therapy (CBT)
Number of subjects: 0
Study: 31379701

Group type: EXPERIMENTAL
Intervention: Interferon Beta 1b
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31379715

Group type: EXPERIMENTAL
Intervention: Tractography-based grading scale for AVMs
Number of subjects: 0
Study: 31379734

Group type: EXPERIMENTAL
Intervention: Subcutaneous Pasireotide
Number of subjects: 0
Study: 31380382

Group type: EXPERIMENTAL
Intervention: Novel Microbial-Based Immunotherapy
Number of subjects: 0
Study: 31380561

Group type: EXPERIMENTAL
Intervention: Mediterranean diet adherence (high score)
Number of subjects: 67332
Study: 31380687

Group type: EXPERIMENTAL
Intervention: Depressive symptoms
Number of subjects: 782
Study: 31381524

Group type: EXPERIMENTAL
Intervention: HD-DBS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TRIHEP3
Number of subjects: 0
Study: 31381526

Group type: EXPERIMENTAL
Intervention: AVXS-101 (onasemnogene abeparvovec)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Natural history cohort (NN101)
Number of subjects: 12
Study: 31381880

Group type: EXPERIMENTAL
Intervention: 4-point LUS method (two bilateral positive points)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 6-point LUS method
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 8-point LUS method (≥ 1 bilateral positive point)
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: 28-point LUS method (B-line count ≥ 30)
Number of subjects: 117
Study: 31382020

Group type: EXPERIMENTAL
Intervention: Omalizumab therapy (mean dosage 473 mg every 4 weeks, mean duration 2.49 years)
Number of subjects: 198
Study: 31382765

Group type: EXPERIMENTAL
Intervention: Paired serial positron emission tomography-coronary computed tomography angiography imaging
Number of subjects: 30
Study: 31382880

Group type: EXPERIMENTAL
Intervention: Frailty and complexity computation algorithms derived from the interRAI-HC assessments.
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Clinical assessment protocols for use by homecare nurses.
Number of subjects: 3

Group type: COMPARATOR
Intervention: InterRAI-HC assessments at three measurement occasions.
Number of subjects: 3
Study: 31382942

Group type: EXPERIMENTAL
Intervention: Warfarin educational video delivered on an electronic tablet (iPad)
Number of subjects: 18
Study: 31383691

Group type: EXPERIMENTAL
Intervention: Caesarean section (CS)
Number of subjects: 39026

Group type: COMPARATOR
Intervention: Vaginal delivery
Number of subjects: 39026

Group type: EXPERIMENTAL
Intervention: Prolonged and obstructed labour as the reason for CS
Number of subjects: 39026
Study: 31383812

Group type: EXPERIMENTAL
Intervention: Irinotecan and etoposide (oral etoposide at 50 mg/day on days 1-14 and intravenous irinotecan at 100 mg/m2)
Number of subjects: 31
Study: 31383903

Group type: EXPERIMENTAL
Intervention: Frail participants
Number of subjects: 170

Group type: EXPERIMENTAL
Intervention: Pre-frail participants
Number of subjects: 170

Group type: COMPARATOR
Intervention: Frail and pre-frail participants
Number of subjects: 170
Study: 31384309

Group type: EXPERIMENTAL
Intervention: Chloroquine (80 mg/day) for 1 year
Number of subjects: 141

Group type: EXPERIMENTAL
Intervention: Chloroquine (dose escalations in 3-week intervals)
Number of subjects: 141

Group type: COMPARATOR
Intervention: Placebo for 1 year
Number of subjects: 141
Study: 31384310

Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg/day
Number of subjects: 98

Group type: COMPARATOR
Intervention: Glibenclamide 5 mg/day
Number of subjects: 98
Study: 31384312

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with docetaxel and cyclophosphamide (75/600 mg/m2) for four 3-weekly cycles
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Bevacizumab in combination with docetaxel and cyclophosphamide
Number of subjects: 106
Study: 31384956

Group type: EXPERIMENTAL
Intervention: Euthyroid Graves' disease patients
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 62
Study: 31384986

Group type: EXPERIMENTAL
Intervention: Sofosbuvir/daclatasvir with ribavirin
Number of subjects: 67

Group type: COMPARATOR
Intervention: Sofosbuvir/daclatasvir without ribavirin
Number of subjects: 67
Study: 31385109

Group type: EXPERIMENTAL
Intervention: Anti-endothelin B receptor antibody-drug conjugate DEDN6526A; specific dosage and duration not mentioned.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified; details on control treatment not available.
Number of subjects: 0
Study: 31385163

Group type: EXPERIMENTAL
Intervention: DOACs
Number of subjects: 774

Group type: COMPARATOR
Intervention: VKAs
Number of subjects: 774
Study: 31385389

Group type: EXPERIMENTAL
Intervention: Standard course of systemic corticosteroid and antibiotic treatment
Number of subjects: 346

Group type: EXPERIMENTAL
Intervention: Eosinophil count <0.144 × 10^9/L
Number of subjects: 346
Study: 31385428

Group type: EXPERIMENTAL
Intervention: EHR-derived AECOPD episodes
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: eCRF-derived moderate/severe AECOPD episodes
Number of subjects: 2269
Study: 31385427

Group type: EXPERIMENTAL
Intervention: Ultrathin stents
Number of subjects: 843

Group type: COMPARATOR
Intervention: PF-BESs
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ultrathin stents (in ULM group)
Number of subjects: 843

Group type: COMPARATOR
Intervention: PF-BESs (in ULM group)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ultrathin stents (in non-ULM group)
Number of subjects: 843

Group type: COMPARATOR
Intervention: PF-BESs (in non-ULM group)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ultrathin stents (two-stent strategy)
Number of subjects: 843

Group type: COMPARATOR
Intervention: PF-BESs (two-stent strategy)
Number of subjects: 843

Group type: EXPERIMENTAL
Intervention: Ultrathin stents (1 month DAPT)
Number of subjects: 843

Group type: COMPARATOR
Intervention: PF-BESs (1 month DAPT)
Number of subjects: 843
Study: 31385617

Group type: EXPERIMENTAL
Intervention: Maribavir (400 mg twice daily for 8 days)
Number of subjects: 18
Study: 31386042

Group type: EXPERIMENTAL
Intervention: Dyadic yoga (DY) intervention
Number of subjects: 20

Group type: COMPARATOR
Intervention: Waitlist control (WLC) group
Number of subjects: 20
Study: 31386061

Group type: EXPERIMENTAL
Intervention: Central review of cognitive test scoring
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Hopkins Verbal Learning Test-Revised
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Controlled Oral Word Association
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Trail Making Test-A
Number of subjects: 500

Group type: EXPERIMENTAL
Intervention: Trail Making Test-B
Number of subjects: 500

Group type: COMPARATOR
Intervention: Onsite electronic data entry without central review
Number of subjects: 500
Study: 31386157

Group type: COMPARATOR
Intervention: Dietary pattern high in soy, vegetables, fruits, tea, tomato products, bread, fish, margarine, and dairy; low in rice, red meat, coffee, alcohol, sugar-sweetened beverages, and eggs.
Number of subjects: 711
Study: 31386611

Group type: EXPERIMENTAL
Intervention: Response- and biology-based therapy
Number of subjects: 404
Study: 31387539

Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgG assay
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgA assay
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgM assay
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Galactomannan (GM) test
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Aspergillus-specific IgG, IgA, IgM assays and GM test cut-off values
Number of subjects: 202
Study: 31387577

Group type: EXPERIMENTAL
Intervention: Physical activity interventions
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Qualitative data collection from medical staff
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Quantitative data collection at diagnosis, 6 months, and 1 year
Number of subjects: 693

Group type: EXPERIMENTAL
Intervention: Retrospective study of societal and policy factors
Number of subjects: 693
Study: 31387885

Group type: EXPERIMENTAL
Intervention: Chemotherapy and cetuximab
Number of subjects: 65
Study: 31388343

Group type: EXPERIMENTAL
Intervention: Breastfeeding experience of mothers of preterm infants
Number of subjects: 270
Study: 31388454

Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg monotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ASP8232 40 mg and monthly intravitreal ranibizumab 0.3 mg combination therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Monthly intravitreal ranibizumab 0.3 mg monotherapy
Number of subjects: 0
Study: 31388598

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) programme, 2-h class, once a week for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supervised exercise programme (SEP) consisting solely of other IC patients
Number of subjects: 0
Study: 31388661

Group type: EXPERIMENTAL
Intervention: mHealth clinical decision-making support intervention
Number of subjects: 65831

Group type: COMPARATOR
Intervention: Control (no mHealth intervention)
Number of subjects: 65831
Study: 31388703

Group type: EXPERIMENTAL
Intervention: Intravenous metamizole (10 mg/kg)
Number of subjects: 25
Study: 31389718

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy
Number of subjects: 0
Study: 31390004

Group type: EXPERIMENTAL
Intervention: Corneal nerve branch density (CNBD) in patients with painful DSPN
Number of subjects: 162

Group type: COMPARATOR
Intervention: Corneal nerve fiber density and corneal nerve fiber length in both DSPN types
Number of subjects: 162

Group type: COMPARATOR
Intervention: Associations of corneal confocal microscopy (CCM) measures with nerve conduction (NC) and cold perception threshold
Number of subjects: 162
Study: 31390128

Group type: EXPERIMENTAL
Intervention: Participants with vascular-related diseases (hypertension, diabetes, CAD, stroke, PAD)
Number of subjects: 13798

Group type: EXPERIMENTAL
Intervention: Participants with each vascular-related disease
Number of subjects: 13798

Group type: EXPERIMENTAL
Intervention: Participants with hypertension
Number of subjects: 13798

Group type: EXPERIMENTAL
Intervention: Participants with vascular-related diseases after adjustment for hypertension
Number of subjects: 13798

Group type: COMPARATOR
Intervention: Participants without vascular-related diseases
Number of subjects: 13798
Study: 31390274

Group type: EXPERIMENTAL
Intervention: Gemcitabine-eribulin combination treatment
Number of subjects: 24
Study: 31390282

Group type: EXPERIMENTAL
Intervention: Patient Portal Intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31390982

Group type: EXPERIMENTAL
Intervention: Tidal volume challenge (V)
Number of subjects: 38
Study: 31391005

Group type: EXPERIMENTAL
Intervention: Zika virus infection during pregnancy (symptomatic confirmed by ZIKV RNA and/or IgM)
Number of subjects: 10000
Study: 31391045

Group type: EXPERIMENTAL
Intervention: Higher HOMA-IR levels
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Impaired fasting glucose (IFG) and impaired glucose tolerance (IGT)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: HOMA-IR
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: HOMA-IR and IGT interaction
Number of subjects: 485
Study: 31391177

Group type: EXPERIMENTAL
Intervention: Haematopoietic stem cell transplantation (HSCT)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Monthly cyclophosphamide (CYC) treatment
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: HSCT
Number of subjects: 62
Study: 31391203

Group type: EXPERIMENTAL
Intervention: Four diabetes medications added to metformin
Number of subjects: 5047

Group type: COMPARATOR
Intervention: Metformin
Number of subjects: 5047
Study: 31391226

Group type: EXPERIMENTAL
Intervention: benralizumab
Number of subjects: 0
Study: 31391334

Group type: EXPERIMENTAL
Intervention: sorafenib therapy
Number of subjects: 30
Study: 31391862

Group type: EXPERIMENTAL
Intervention: C-117 formula
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 31391947

Group type: EXPERIMENTAL
Intervention: Non-medical psychosocial counselling (PSY)
Number of subjects: 287

Group type: COMPARATOR
Intervention: Enhanced usual care (EUC)
Number of subjects: 287
Study: 31391949

Group type: EXPERIMENTAL
Intervention: DMF 240 mg twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31392048

Group type: EXPERIMENTAL
Intervention: Lanreotide monotherapy
Number of subjects: 91

Group type: COMPARATOR
Intervention: Long-acting octreotide
Number of subjects: 91
Study: 31392200

Group type: EXPERIMENTAL
Intervention: Liver depot gene therapy using an AAV vector for GAA production
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enzyme replacement therapy (ERT) with recombinant human acid α-glucosidase (GAA)
Number of subjects: 0
Study: 31392500

Group type: EXPERIMENTAL
Intervention: Gait parameters measured in patients with axSpA
Number of subjects: 60

Group type: COMPARATOR
Intervention: Healthy age- and sex-matched controls
Number of subjects: 60
Study: 31392710

Group type: EXPERIMENTAL
Intervention: Selective head cooling (SHC)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Whole body cooling (WBC)
Number of subjects: 78
Study: 31393220

Group type: EXPERIMENTAL
Intervention: Upper extremity function assessment in patients with multiple sclerosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Shoulder position sense assessment in patients with multiple sclerosis
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Disability level assessment in patients with multiple sclerosis
Number of subjects: 0
Study: 31393222

Group type: EXPERIMENTAL
Intervention: Pharmacogenetic testing
Number of subjects: 0
Study: 31393873

Group type: EXPERIMENTAL
Intervention: Honour killing reported in family (Afghanistan)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing reported in family (oPT)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with borrowing because of hunger (Afghan married women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with easier access to money in emergency (Afghan married women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with intimate partner violence (Afghan married women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with IPV and mother-in-law violence (Afghan married women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with easier access to money in emergency (Afghan unmarried women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with household violence (Afghan unmarried women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with more childhood traumas (Afghan unmarried women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with more patriarchal personal gender attitudes (Afghan unmarried women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with experiencing IPV (oPT married women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with borrowing and experiencing IPV (oPT married women)
Number of subjects: 1996

Group type: EXPERIMENTAL
Intervention: Honour killing associated with borrowing because of hunger (oPT unmarried women)
Number of subjects: 1996
Study: 31394007

Group type: EXPERIMENTAL
Intervention: Autologous hematopoietic stem cell transplantation (HSCT) after conditioning with cyclophosphamide and rituximab.
Number of subjects: 617

Group type: COMPARATOR
Intervention: Not applicable (no control group mentioned).
Number of subjects: 617
Study: 31394574

Group type: EXPERIMENTAL
Intervention: Second dose of investigational trivalent CRM197-glycoconjugate GBS vaccine (targeting serotypes Ia/Ib/III)
Number of subjects: 80
Study: 31394594

Group type: EXPERIMENTAL
Intervention: Auditory/vestibular evaluations (rotational chair, videonystagmography, computerized dynamic posturography, vestibular evoked myogenic potentials, retinal fundoscopy)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Auditory/vestibular evaluations
Number of subjects: 75
Study: 31394596

Group type: EXPERIMENTAL
Intervention: mTBI participants with measurable hearing loss
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: mTBI participants with no measurable hearing loss
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: mTBI participants with no measurable hearing loss but reported hearing concerns
Number of subjects: 69

Group type: COMPARATOR
Intervention: Control group (adults without brain injury)
Number of subjects: 69
Study: 31394598

Group type: EXPERIMENTAL
Intervention: mTBI participants
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: mTBI participants with high anxiety or post-traumatic stress
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: mTBI participants with high anxiety, post-traumatic stress or depression
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Subset of mTBI group with abnormal tandem gait and high anxiety
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: mTBI group
Number of subjects: 71

Group type: COMPARATOR
Intervention: Normative controls
Number of subjects: 71
Study: 31394828

Group type: EXPERIMENTAL
Intervention: Serum Adipokines, Growth Factors, and Cytokines
Number of subjects: 50
Study: 31394994

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (IVT) only
Number of subjects: 1135

Group type: EXPERIMENTAL
Intervention: IVT followed by EVT
Number of subjects: 1135
Study: 31395011

Group type: EXPERIMENTAL
Intervention: Intraoperative Burst Suppression periods
Number of subjects: 97
Study: 31395019

Group type: EXPERIMENTAL
Intervention: Transitional care coordination (TCC) and patient navigation intervention
Number of subjects: 84
Study: 31395089

Group type: EXPERIMENTAL
Intervention: Pembrolizumab at 2 mg/kg every 3 weeks, 10 mg/kg every 2 weeks, 10 mg/kg every 3 weeks, or 200 mg every 3 weeks.
Number of subjects: 3655

Group type: EXPERIMENTAL
Intervention: Adjuvant pembrolizumab at 200 mg every 3 weeks after complete resection in patients with stage III melanoma.
Number of subjects: 3655
Study: 31395100

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (Pembrolizumab + Axitinib, AGEN1884, Pembrolizumab)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (specific mention of AGEN1884)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (Pembrolizumab, switched to Nivolumab/Ipilimumab)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Checkpoint inhibitors (general)
Number of subjects: 7